Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and Procter & Gamble (NYSE:PG – Get Free Report) are both consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
Institutional and Insider Ownership
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 65.8% of Procter & Gamble shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 0.2% of Procter & Gamble shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Niagen Bioscience and Procter & Gamble’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 12.39% | 17.95% | 13.17% |
| Procter & Gamble | 18.44% | 31.36% | 13.09% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 3 | 1 | 3.00 |
| Procter & Gamble | 0 | 11 | 13 | 0 | 2.54 |
Niagen Bioscience currently has a consensus target price of $10.33, indicating a potential upside of 221.91%. Procter & Gamble has a consensus target price of $161.19, indicating a potential upside of 12.58%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, equities analysts clearly believe Niagen Bioscience is more favorable than Procter & Gamble.
Risk and Volatility
Niagen Bioscience has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Procter & Gamble has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Valuation & Earnings
This table compares Niagen Bioscience and Procter & Gamble”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | 1.98 | $17.38 million | $0.18 | 17.83 |
| Procter & Gamble | $87.03 billion | 3.82 | $16.05 billion | $6.62 | 21.63 |
Procter & Gamble has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than Procter & Gamble, indicating that it is currently the more affordable of the two stocks.
Summary
Procter & Gamble beats Niagen Bioscience on 9 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
About Procter & Gamble
Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
